Ticagrelor coadministered with acetylsalicylic acid 75-100mg is indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS) [unstable angina, non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) including patients managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Ticagrelor 90 mg
Up to 18 Years
The safety and efficacy of ticagrelor in children below the age of 18 years have not been established. No data are available.
18 Years Old and Above
Patients taking ticagrelor should also take a daily low maintenance dose of acetylsalicyclic acid 75-100 mg, unless specifically contraindicated. For acute coronary syndromes, ticagrelor treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
Ticagrelor can be administered with or without food.
No dose adjustment is required in elderly.
Patients with Renal Impairment
No dose adjustment is necessary for patients with renal impairment. No information is available concerning treatment of patients on renal dialysis and therefore ticagrelor is not recommended in these patients.
Patients with Hepatic Impairment
Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated. Only limited information is available in patients with moderate hepatic impairment. Dose adjustment is not recommended, but ticagrelor should be used with caution. No dose adjustment is necessary for patients with mild hepatic impairment.